湖南汉森制药股份有限公司 关于2024年度拟不进行利润分配的 专项说明

Group 1 - The company held the sixth board meeting and the seventh supervisory board meeting on April 24, 2025, to review and approve the 2024 profit distribution plan, which will be submitted to the 2024 annual general meeting for approval [1][4]. - The audit committee found that the profit distribution plan aligns with the company's actual situation and does not harm the interests of shareholders, especially minority shareholders [1][3]. - The board of directors believes the profit distribution plan considers the company's current and future investment needs and is beneficial for the company's normal operations and healthy development [2][3]. Group 2 - The company achieved a net profit attributable to shareholders of 220,244,409.11 yuan for 2024, with the parent company reporting a net profit of 152,528,625.53 yuan [5]. - The profit distribution plan proposes not to distribute cash dividends, issue bonus shares, or increase capital from reserves, with undistributed profits carried forward to the next year [5][6]. - The decision to not distribute dividends is based on the company's development strategy and the need to maintain operational stability and risk resilience [6]. Group 3 - The company approved the use of idle self-owned funds for cash management, with a limit of up to 400 million yuan to purchase low-risk financial products or structured deposits [9][10]. - The purpose of this cash management is to enhance the efficiency of fund usage without affecting normal operations, thereby increasing returns for the company and its shareholders [9][10]. - The board and supervisory board agreed that the current financial situation is stable, and the proposed cash management will not adversely affect the company's operations [17][38]. Group 4 - The supervisory board meeting also approved the 2024 annual financial settlement report, which reflects the company's financial status and operating results accurately [28][31]. - The internal control evaluation report for 2024 was approved, indicating no significant deficiencies in the internal control system [37]. - The company will implement the cash management decision within a 12-month period from the approval date [13].